STAT November 30, 2023
Manil Suri and Daniel Morgan

Worried about your health? You can now avail yourself of noninvasive diagnostics that claim to screen for rare birth defects, cancer-associated mutations, and even Alzheimer’s. Even before the Covid pandemic, a 2018 paper reported that new genetic tests, many of them for increasingly rare conditions, were being released at the rate of 10 a day. These tests can be both sold direct to consumer and ordered by your physician.

A significant factor helping drive this entrepreneurial proliferation is that so-called lab-developed tests, which are designed, manufactured, and used in the same facility, have been exempt from FDA oversight. Consequently, such “LDTs” can be quickly brought to market without the FDA review of their effectiveness, labeling accuracy, and marketing claims required...

Today's Sponsors

Venturous
Got healthcare questions? Just ask Transcarent

Today's Sponsor

Venturous

 
Topics: FDA, Govt Agencies, Patient / Consumer, Provider
Screenagers to Silver Surfers: How each generation clicks with care
At Current Prices GLP-1s Aren’t Cost-Effective, Limiting Access To Patients
AI that can match humans at any task will be here in five to 10 years, Google DeepMind CEO says
Why is longevity suddenly so hot?
New Law Extends Telehealth Flexibilities Another 6 Months

Share This Article